Lirafugratinib

DB18300InvestigationalSmall molecule

Lirafugratinib: Overview.

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 2
Curator reviewed
Formula / weight: C₂₈H₂₄FN₇O₂ · 509.545 g/mol (avg)
Also known as: 2-Propenamide, N-[4-[4-amino-5-[3-fluoro-4-[(4-methyl-2-pyrimidinyl)oxy]phenyl]-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-2-methyl- · N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide · N-[4-(4-amino-5-{3-fluoro-4-[(4-methylpyrimidin-2- yl)oxy]phenyl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6- yl)phenyl]-2-methylprop-2-enamide
Code names: RLY-4008

Resolves to

Compound

Structure

InChIKeyXOQVZSSDIQQUGO-UHFFFAOYSA-NSMILESCN1C2=NC=NC(N)=C2C(=C1C1=CC=C(NC(=O)C(C)=C)C=C1)C1=CC=C(OC2=NC=CC(C)=N2)C(F)=C1

Targets

What you can answer from here — as of September 29, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lirafugratinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.